Team:MIT

From 2014.igem.org

(Difference between revisions)
 
(55 intermediate revisions not shown)
Line 17: Line 17:
<br>
<br>
<table width=95% align=center>
<table width=95% align=center>
-
<tr><td><h3 style="font-size:20px" align=center>Improving the Diagnosis and Treatment of</h3></td></tr>
+
 
-
<tr><td><h3 style="font-size:50px" align=center>ALZHEIMER'S DISEASE</h3></td></tr>
+
<tr><td><h3 style="font-size:20px; color:teal" align=center><b>IMPROVING THE DIAGNOSIS AND TREATMENT OF</u></h3></td></tr>
 +
<tr><td><h3 style="font-size:50px; color:teal" align=center><b>ALZHEIMER'S DISEASE</b></h3></td></tr>
<tr><td><h3 style="font-size:25px" align=right><br></h3></td></tr>
<tr><td><h3 style="font-size:25px" align=right><br></h3></td></tr>
 +
 +
<table width=95% align=center>
<table width=95% align=center>
Line 28: Line 31:
</tr>
</tr>
<tr>
<tr>
-
<td width=33.3%><p style="font-size:15px; color:black" align=top> Neurodegenerative disease</p></td>
+
<td width=33.3%><p style="font-size:12px; color:teal" align=top><b> NEURODEGENERATIVE <br>DISEASE </b></p></td>
-
<td width=33.3%><p style="font-size:15px; color:black"> Sixth leading cause of death in the US</p></td>
+
<td width=33.3%><p style="font-size:12px; color:teal"><b> 6th LEADING CAUSE OF<br> DEATH IN THE U.S.</b></p></td>
-
<td width=33.3%><p style="font-size:15px; color:black"> Current diagnostics and therapeutics <br> are ineffective</p></td>
+
<td width=33.3%><p style="font-size:12px; color:teal"><b> CURRENT DIAGNOSTICS AND<br> THERAPEUTICS ARE INEFFECTIVE</b></p></td>
</tr>
</tr>
</table>
</table>
 +
<br><br>
<table width=90% align=center>
<table width=90% align=center>
<tr><td><br><p style="font-size:15px" align=left><b>Alzheimer's disease is the sixth leading cause of death</b> in the United States, affecting more than 5 million Americans and resulting in the deaths of 500,000 people every year (Alzheimer's Association).  Though one in three seniors dies with this disease (Alzheimer's Association), it currently has no cure, and, according to the clinicians that we interviewed, existing diagnosis methods are unreliable.  <b>MIT iGEM 2014 is working to change this situation.</b>  We set out to devise a way to diagnose Alzheimer's disease using biological rather than psychological tests and to invent a treatment mechanism that would capitalize on recent findings about the molecular pathology of the disease.  Using the principles of synthetic biology, we designed a system that <b>detects molecular biomarkers</b> for Alzheimer's disease and <b>alters the levels of key enzymes</b> in response.  Our dynamic system combats Alzheimer's disease only when the disease is detected, providing a specific, state-sensitive treatment. In the future, an approach like ours could provide a solution for patients suffering from the debilitating effects of Alzheimer's disease and improve the lives of their caretakers and family.
<tr><td><br><p style="font-size:15px" align=left><b>Alzheimer's disease is the sixth leading cause of death</b> in the United States, affecting more than 5 million Americans and resulting in the deaths of 500,000 people every year (Alzheimer's Association).  Though one in three seniors dies with this disease (Alzheimer's Association), it currently has no cure, and, according to the clinicians that we interviewed, existing diagnosis methods are unreliable.  <b>MIT iGEM 2014 is working to change this situation.</b>  We set out to devise a way to diagnose Alzheimer's disease using biological rather than psychological tests and to invent a treatment mechanism that would capitalize on recent findings about the molecular pathology of the disease.  Using the principles of synthetic biology, we designed a system that <b>detects molecular biomarkers</b> for Alzheimer's disease and <b>alters the levels of key enzymes</b> in response.  Our dynamic system combats Alzheimer's disease only when the disease is detected, providing a specific, state-sensitive treatment. In the future, an approach like ours could provide a solution for patients suffering from the debilitating effects of Alzheimer's disease and improve the lives of their caretakers and family.
<br><br>
<br><br>
-
<tr><td><br><h3 style="font-size:35px" align=center><u>DETECTION  →  TREATMENT  →  DELIVERY</u></h3></td></tr>
 
-
<tr><td><br></td></tr>
 
</table>
</table>
<br><br>
<br><br>
<table width=95% align=center>
<table width=95% align=center>
-
<tr><td colspan=3><h3 style="font-size:25px">DETECTION</h3></td>
+
<tr><td colspan=3><h3 style="font-size:25px; color:teal">DETECTION</h3></td>
</tr>
</tr>
<tr>
<tr>
 +
<br><br>
<td width=33.3%><a href="https://2014.igem.org/Team:MIT/Protein_sensor"><img src="https://static.igem.org/mediawiki/2014/e/e9/MIT_Native_receptor_homepage.png"><br><p style="font-size:12px; color:black"><b>NATIVE β-AMYLOID RECEPTOR</b></p></a></td>
<td width=33.3%><a href="https://2014.igem.org/Team:MIT/Protein_sensor"><img src="https://static.igem.org/mediawiki/2014/e/e9/MIT_Native_receptor_homepage.png"><br><p style="font-size:12px; color:black"><b>NATIVE β-AMYLOID RECEPTOR</b></p></a></td>
<td width=33.3%><a href="https://2014.igem.org/Team:MIT/BCR"><img src="https://static.igem.org/mediawiki/2014/f/f8/MIT_bcr_homepage.png"><br><p style="font-size:12px; color:black"><b>ENGINEERED B-CELL RECEPTOR</b></p></a></td>
<td width=33.3%><a href="https://2014.igem.org/Team:MIT/BCR"><img src="https://static.igem.org/mediawiki/2014/f/f8/MIT_bcr_homepage.png"><br><p style="font-size:12px; color:black"><b>ENGINEERED B-CELL RECEPTOR</b></p></a></td>
-
<td width=33.3%><a href="https://2014.igem.org/Team:MIT/miRNA"><img src="https://static.igem.org/mediawiki/2014/8/88/MIT_mirna_homepage.png"><br><p style="font-size:12px; color:black"><b>miRNA SENSORS</b></p></a></td>
+
<td width=33.3%><a href="https://2014.igem.org/Team:MIT/miRNA"><img src="https://static.igem.org/mediawiki/2014/8/88/MIT_mirna_homepage.png"><br><p style="font-size:12px; color:black"><b>miRNA DETECTION</b></p></a></td>
<tr>
<tr>
</table>
</table>
-
<br>
 
-
<table width=75% align=center>
 
-
<tr><td><h3 style="font-size:25px">TREATMENT</h3></td>
 
-
<td><h3 style="font-size:25px">DELIVERY</h3></td>
 
-
</tr>
 
<br><br>
<br><br>
 +
<table width=74.5% align=center>
 +
<tr><td><h3 style="font-size:23.5px; color:teal">TREATMENT</h3></td>
 +
<td><h3 style="font-size:23.5px; color:teal">DELIVERY</h3></td>
 +
</tr>
<tr>
<tr>
<td width=50%><a href="https://2014.igem.org/Team:MIT/Treatment"><img src="https://static.igem.org/mediawiki/2014/1/19/MIT_treatment_homepage.png"></a></td>
<td width=50%><a href="https://2014.igem.org/Team:MIT/Treatment"><img src="https://static.igem.org/mediawiki/2014/1/19/MIT_treatment_homepage.png"></a></td>
<td width=50%><a href="https://2014.igem.org/Team:MIT/Delivery"><img src="https://static.igem.org/mediawiki/2014/0/06/MIT_future_homepage.png"></a></td>
<td width=50%><a href="https://2014.igem.org/Team:MIT/Delivery"><img src="https://static.igem.org/mediawiki/2014/0/06/MIT_future_homepage.png"></a></td>
</tr>
</tr>
-
<tr><td><a href="https://2014.igem.org/Team:MIT/Treatment"><p style="font-size:12px; color:black"><b>REGULATING β-AMYLOID PRODUCTION</b><br><b>AND DEGRADATION</b></p></a></td>
+
<tr><td><a href="https://2014.igem.org/Team:MIT/Treatment"><p style="font-size:12px; color:black"><b>REGULATING β-AMYLOID PRODUCTION<br>AND DEGRADATION</b></p></a></td>
<td><a href="https://2014.igem.org/Team:MIT/Delivery"><p style="font-size:12px; color:black"><b>DELIVERING THE CIRCUIT</b></p></a></td>
<td><a href="https://2014.igem.org/Team:MIT/Delivery"><p style="font-size:12px; color:black"><b>DELIVERING THE CIRCUIT</b></p></a></td>
</tr>
</tr>
</table>
</table>
<br>
<br>
-
 
+
<tr><td><p style="font-size:12px" align=center><i>Attributions: Kathryn Brink, Alexa Garcia, Shinjini Saha<br>Kathryn Brink (Content), Alexa Garcia (Content), Shinjini Saha (Illustrations)<br> Special mention: Shinjini Saha (Illustrations for entire website)</i></p></td></tr>
</body>
</body>
</table>
</table>

Latest revision as of 03:54, 18 October 2014

 


Image Map



IMPROVING THE DIAGNOSIS AND TREATMENT OF

ALZHEIMER'S DISEASE


NEURODEGENERATIVE
DISEASE

6th LEADING CAUSE OF
DEATH IN THE U.S.

CURRENT DIAGNOSTICS AND
THERAPEUTICS ARE INEFFECTIVE




Alzheimer's disease is the sixth leading cause of death in the United States, affecting more than 5 million Americans and resulting in the deaths of 500,000 people every year (Alzheimer's Association). Though one in three seniors dies with this disease (Alzheimer's Association), it currently has no cure, and, according to the clinicians that we interviewed, existing diagnosis methods are unreliable. MIT iGEM 2014 is working to change this situation. We set out to devise a way to diagnose Alzheimer's disease using biological rather than psychological tests and to invent a treatment mechanism that would capitalize on recent findings about the molecular pathology of the disease. Using the principles of synthetic biology, we designed a system that detects molecular biomarkers for Alzheimer's disease and alters the levels of key enzymes in response. Our dynamic system combats Alzheimer's disease only when the disease is detected, providing a specific, state-sensitive treatment. In the future, an approach like ours could provide a solution for patients suffering from the debilitating effects of Alzheimer's disease and improve the lives of their caretakers and family.





DETECTION


NATIVE β-AMYLOID RECEPTOR


ENGINEERED B-CELL RECEPTOR


miRNA DETECTION



TREATMENT

DELIVERY

REGULATING β-AMYLOID PRODUCTION
AND DEGRADATION

DELIVERING THE CIRCUIT


Attributions: Kathryn Brink, Alexa Garcia, Shinjini Saha
Kathryn Brink (Content), Alexa Garcia (Content), Shinjini Saha (Illustrations)
Special mention: Shinjini Saha (Illustrations for entire website)